Clinical trial Recruiting at 1 site Observational Ages 60 to 100

Monitoring blood markers in elderly patients with acute leukemia after chemotherapy

Official title: Monitoring Circulating Tumor DNA After Chemotherapy in Elderly Patients With Acute Leukemia

Run by Navy General Hospital, Beijing · NCT04157569 · Data updated 2026-11-12

This study is testing if measuring certain blood markers can help doctors understand how well chemotherapy is working for older patients with acute leukemia.

More Acute Leukemia trials

Quick facts

Study typeObservational
Ages60 Years to 100 Years
SexAll
Enrollment200 (estimated)
SponsorNavy General Hospital, Beijing
Academic / other
Drugs / interventionsChemotherapy
Locations1 site (Beijing)
StatusRecruiting
StartedNovember 5, 2019
Main results expectedDecember 31, 2024
Study endsDecember 31, 2029
Registry record updatedFebruary 25, 2020
Trial IDNCT04157569 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are elderly male patients aged 60 years and older who have been diagnosed with acute leukemia.

Probably not a fit

Patients who are pregnant, HIV positive, or aged 100 years and older may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to monitor circulating tumor DNA (CtDNA) levels in elderly patients diagnosed with acute leukemia following chemotherapy treatment. Utilizing the droplet digital PCR (ddPCR) method, the study will quantify the mutant allele frequency (MAF) in peripheral blood plasma to assess the clinical significance of CtDNA in this patient population. The findings may provide insights into treatment efficacy and disease progression in elderly patients.

Why it matters

Potential benefit: If successful, this study could enhance the understanding of treatment responses in elderly acute leukemia patients, potentially leading to improved monitoring and management strategies.

How similar studies have gone: While the use of CtDNA monitoring in cancer treatment is gaining traction, this specific approach in elderly acute leukemia patients is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Written informed consent
* Male
* not pregnant female
* patients \>=60 years old
* Diagnosis of acute leukemia

Exclusion Criteria:

* Pregnancy
* HIV positive
* patients \>=100 years old

Where it's running

  • Navy General Hospital
    Beijing, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.